A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Inclusion Criteria: * Is diagnosed with CP/CPPS with symptoms for at least 3 months over the last 6 months * Has a NIH-CPSI total score of at least 15 * A score of at least 4 on question 4 (pain) in the NIH-CPSI * Reports pain on palpation of the prostate or the perineum/genital area * Answers "yes" to at least 1 out of 6 items in question 1 and 2 of the NIH-CPSI * Is willing to comply with study requirements such as completing the micturition and symptoms diary and attend all study visits Exclusion Criteria: * Isolated unilateral testicular, penile or scrotal pain as a solitary symptom of pelvic pain * Urinary Tract Infection (UTI) or prostate infection found at screening using the pre- and post massage test or in the last 3 months prior to screening * Any prior prostate and or bladder intervention within 3 months prior to screening * Lower urinary tract malignancy (suspected), such as positive (micro) hematuria in urine sediment or Prostate Specific Antigen (PSA) \>4 ng/mL * Symptomatic urethral stricture or symptomatic bladder or urethral calculi, severe bladder outlet obstruction, overactive bladder with incontinence or Post Void Residual volume, greater than 150 mL * Clinically significant abnormalities on transabdominal ultrasound of bladder and prostate or neurological disease or defect affecting bladder function * Currently active sexually transmittable disease * Substance abuse or any use of delta-9-tetrahydrocannabinol (THC) as assessed by a positive urine test f…